chlorzoxazone (parafon forte dsc) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Chlorzoxazone is a centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles. Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.   NCATS

Chemistry

  • SMILES: ClC1=CC2=C(OC(=O)N2)C=C1
  • InChIKey: TZFWDZFKRBELIQ-UHFFFAOYSA-N
  • Mol. Mass: 169.565
  • ALogP: 1.77
  • ChEMBL Molecule:
    chlorzoxazone  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.2847 - $10.5684
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-hydroxy-5-chlorobenzoxazole | 5-chloro-2(3h)-benzoxazolone | 5-chloro-2-benzoxazolinone | 5-chloro-2-benzoxazolol | 5-chloro-2-benzoxazolone | 5-chloro-2-hydroxybenzoxazole | 5-chloro-3h-benzooxazol-2-one | 5-chlorobenzoxazolidone | 5-chlorobenzoxazolin-2-one | chloroxazone | chlorzoxane | chlorzoxazon | chlorzoxazona | chlorzoxazone | chlorzoxazonum | clorzoxazona | clorzoxazone | paraflex | parafon | parafon forte | parafon-forte | parafon forte dsc | strifon | strifon forte dsc

Organizations (28)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Spasm (approved 1988)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Alcoholism (Phase 4)

Chlorzoxazone (Phase 4)

Osteoarthritis, Hip (Phase 4)

Osteoarthritis, Knee (Phase 4)

Pain, Postoperative (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue